Nalsaferon study receives Special Award

 HAVANA, Cuba, Jan 20 (ACN) The study of the Center for Genetic Engineering and Biotechnology (CIGB by its Spanish acronym) "Nalsaferon, new formulation that enhances the innate immune response at mucosal and systemic level for the prophylactic and therapeutic treatment of SARS-COV-2 virus infection," won the Special Award for its scientific impact at the recently concluded Innovation for Development Fair.

Ana Aguilera Barrego, a specialist of the institution, told the Cuban News Agency that the drug is a nasal formulation with recombinant interferon, an active ingredient recognized in Cuba.

The product was used in the country for the treatment of COVID-19 due to its antiviral properties and is indicated for the temporary prophylaxis of SARS-CoV-2 infection in 19 to 80 year-old individuals at high risk of exposure to the virus, such as health personnel, people who are contacts of suspects or confirmed cases and travelers, she said.

She added that the CIGB has continued its development of Nasalferon for its biological actions also as an immunolator.

The scientist commented that the intention is to initiate a new clinical study for the use of Nalsaferon in acute respiratory diseases for the benefit of the population, since this disease is very common in the national territory due to the fact that it is a tropical country.

One purpose is to produce and commercialize this medicine in pharmacies, due to its easy application, without the need of medical personnel, the expert continued.

Aguilera Borrego mentioned that as part of the actions of the Technological Development Group of the CIGB, work is being done to obtain a vaccine against Dengue.